We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+11.19%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$510M
AUM Growth
+$94.9M
Cap. Flow
+$120M
Cap. Flow %
23.47%
Top 10 Hldgs %
49.51%
Holding
57
New
17
Increased
16
Reduced
7
Closed
15

Top Buys

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$22.4M
2
OPTN
OptiNose
OPTN
+$20M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$17.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$13.5M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$18.9M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$13.1M
3
ALKS icon
Alkermes
ALKS
+$11M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.4M
5
TVTX icon
Travere Therapeutics
TVTX
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$38.4M 7.52%
800,000
+200,000
+33% +$7.85M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.06B
$33.5M 6.57%
850,000
– –
RAPT
3
DELISTED
RAPT Therapeutics
RAPT
$28.4M 5.58%
179,571
+140,196
+356% +$22.4M
ALPN
4
DELISTED
Alpine Immune Sciences Inc
ALPN
$26.7M 5.24%
3,637,718
+189,197
+5% +$1.21M
PLRX icon
5
Pliant Therapeutics
PLRX
$64.4M
$25.6M 5.01%
1,322,870
+281,133
+27% +$5.88M
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$15.9B
$25.5M 5%
160,000
-55,000
-26% -$8.06M
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$20.6M 4.04%
160,500
+84,000
+110% +$10.8M
PNT
8
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$18.5M 3.63%
2,541,779
-1,019,205
-29% -$7.56M
NVCR icon
9
PUT
NovoCure
NVCR
$1.73B
$17.7M 3.46%
+241,000
New +$18.1M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.7M 3.46%
+825,000
New +$17.6M
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$16.1M 3.15%
1,019,282
– –
HRTX icon
12
Heron Therapeutics
HRTX
$93.9M
$15.9M 3.12%
6,360,161
+715,000
+13% +$2.3M
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.45B
$15.9M 3.11%
+342,300
New +$13.5M
OPTN
14
DELISTED
OptiNose
OPTN
$14.6M 2.86%
+526,316
New +$20M
VTYX
15
DELISTED
Ventyx Biosciences
VTYX
$13.1M 2.58%
400,695
+130,728
+48% +$3.87M
CINC
16
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$12.5M 2.46%
1,019,153
+717,829
+238% +$17.1M
VKTX icon
17
Viking Therapeutics
VKTX
$3.7B
$12.2M 2.39%
+1,295,034
New +$5.78M
DAWN
18
DELISTED
Day One Biopharmaceuticals
DAWN
$11.7M 2.3%
544,451
+473,830
+671% +$9.72M
PTCT icon
19
PTC Therapeutics
PTCT
$5.64B
$11.5M 2.26%
+302,135
New +$12.6M
JBIO
20
Jade Biosciences
JBIO
$1.2B
$11.1M 2.17%
+10,815
New +$7.85M
TVTX icon
21
Travere Therapeutics
TVTX
$5.2B
$9.99M 1.96%
475,000
-491,108
-51% -$10.4M
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
$9.72M 1.9%
1,550,000
+750,561
+94% +$2.85M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.57B
$9.46M 1.85%
+73,000
New +$8.46M
RCKT icon
24
CALL
Rocket Pharmaceuticals
RCKT
$340M
$8.83M 1.73%
+451,000
New +$8.31M
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
$7.14M 1.4%
1,055,801
-495,918
-32% -$2.66M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Great Point Partners held 57 positions worth $510M, up 23% from $415M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Great Point Partners deployed $120M of net new capital in Q4 2022, opening 17 new positions and adding to 16 existing holdings. Its largest new stake was OptiNose: 526,316 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Alkermes, an estimated $11M trimmed.

  • Great Point Partners's largest Q4 2022 buy was OptiNose: 526,316 shares worth $14.6M.
  • Great Point Partners added most to RAPT Therapeutics in Q4 2022, an estimated $22.4M increase.
  • Great Point Partners's biggest Q4 2022 reduction was Alkermes, cutting an estimated $11M.
  • Great Point Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $18.9M.
  • Great Point Partners's ten largest holdings make up 50% of its $510M portfolio in Q4 2022.
  • Great Point Partners opened 17 new positions and closed 15 in Q4 2022.
  • Great Point Partners's portfolio value rose 23% quarter-over-quarter to $510M.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.